# MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma

> **NCT01415765** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Lymphoma, Diffuse Large-Cell B-cell
- Diffuse, Large B-cell Lymphoma
- Lymphoma, Diffuse Large-Cell
- Large-Cell Lymphoma, Diffuse

## Interventions

- **DRUG:** MLN4924
- **DRUG:** Etoposide
- **DRUG:** Prednisone
- **DRUG:** Vincristine
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Rituximab
- **DRUG:** Filgrastim

## Key facts

- **NCT ID:** NCT01415765
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-07-15
- **Primary completion:** 2014-01-07
- **Final completion:** 2014-01-07
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2019-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01415765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01415765, "MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01415765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*